Eudragit EPO nanoparticles: Application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration

Journal of Biomedical Nanotechnology

Volumn 7, Issue 4, 2011, Pages 590-597

  Khachane, Parag ^a   Date, Abhijit A ^a   Nagarsenker, Mangal S ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

Eudragit EPO; Improved therapeutic efficacy; Meloxicam; Nanoparticles; Poor solubility; Reduced ulcerogenicity

Indexed keywords

ADVERSE EFFECT; ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY EFFECTS; ENCAPSULATION EFFICIENCY; EUDRAGIT; IN-VITRO DISSOLUTION; MELOXICAM; NANOPRECIPITATION METHOD; ORAL ADMINISTRATION; REDUCED ULCEROGENICITY; THERAPEUTIC EFFICACY;

ENCAPSULATION;

NANOPARTICLES;

EUDRAGIT; MELOXICAM; NANOPARTICLE; EUDRAGIT E PO; NANOCAPSULE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMETHACRYLIC ACID DERIVATIVE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FUNCTIONAL MORPHOLOGY; NANOENCAPSULATION; PARTICLE SIZE; PRECIPITATION; ULCEROGENESIS; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; MALE; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT; STOMACH ULCER; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOCAPSULES; NANOTECHNOLOGY; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STOMACH ULCER; THIAZINES; THIAZOLES;

EID: 80052903247     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1322     Document Type: Article

References (33)

1. M. Dittgen, M. Durrani, and K. Lehmann, Acrylic polymers. A review of pharmaceutical applications. STP Pharm. Sci. 7, 403 (1997).
2. H. Valizadeh, A. Nokhodchi, N. Qarakhani, P. Zakeri-Milani, S. Azarmi, D. Hassanzadeh, and R. Löbenberg, Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev. Ind. Pharm. 30, 303 (2004).
3. H. Valizadeh, P. Zakeri-Milani, M. Barzegar-Jalali, G. Mohammadi, M. A. Danesh-Bahreini, K. Adibkia, and A. Nokhodchi, Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev. Ind. Pharm. 33, 45 (2007).
4. C. Goddeeris, T. Willems, K. Houthoofd, J. A. Martens, and G. Van den Mooter, Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100. Eur. J. Pharm. Biopharm. 70, 861 (2008).
5. Y. Sun, Y. Rui, Z. Wenliang, and X. Tang, Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. Int. J. Pharm. 359, 144 (2008).
6. H. He, R. Yang, and X. Tang, In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 36, 681 (2010).
7. Y. K. Lo, C. J. Chen, T. R. Tsai, and T. M. Cham, Comparison of the solubility and dissolution rate between gliclazide solid complex and its nanospheres. Drug Dev. Ind. Pharm. 33, 301 (2007).
8. F. L. Yen, T. H. Wu, L. T. Lin, T. M. Cham, and C. C. Lin, Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl(4)-induced acute liver failure. Pharm. Res. 26, 893 (2009).
9. B. Chellampillai and A. P. Pawar, Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 35, 123 (2011).
10. T. H. Wu, F. L. Yen, L. T. Lin, T. R. Tsai, C. C. Lin, and T. M. Cham, Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int. J. Pharm. 346, 160 (2008).
11. M. Ahmed, D. Khanna, and D. E. Furst, Meloxicam in rheumatoid arthritis. Expert Opin. Drug Metab. Toxicol. 1, 739 (2005).
12. B. J. Gates, T. T. Nguyen, S. M. Setter, and N. M. Davies, Meloxicam: A reappraisal of pharmacokinetics, efficacy and safety. Expert Opin. Pharmacother. 6, 2117 (2005).
13. G. Di Girolamo, M. Farina, M. L. Riberio, D. Ogando, J. Aisemberg, A. R. de los Santos, M. L. Martí, and A. M. Franchi, Effects of cyclooxygenase inhibitor pretreatment on nitric oxide production, nNOS and iNOS expression in rat cerebellum. Br. J. Pharmacol. 139, 1164 (2003).
14. T. Naruse, Y. Nishida, and N. Ishiguro, Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed. Pharmacother. 61, 338 (2007).
15. G. Hanft, D. Türck, S. Scheuerer, and R. Sigmund, Meloxicam oral suspension: A treatment alternative to solid meloxicam formulations. Inflamm. Res. 50, S35 (2001).
16. D. N. Mishra and S. G. Vijaya Kumar, Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk. Yakugaku Zasshi. 126, 495 (2006).
17. S. G. Vijaya Kumar and D. N. Mishra, Analgesic, anti-inflammatory and ulcerogenic studies of meloxicam solid dispersion prepared with polyethylene glycol 6000. Methods Find Exp. Clin. Pharmacol. 28, 419 (2006).
18. S. Baboota, and S. P. Agarwal, Meloxicam complexation with β-cyclodextrin: Influence on the anti-inflammatory and ulcerogenic activity. Pharmazie 58, 73 (2003).
19. B. N. Nalluri, K. P. Chowdary, K. V. Murthy, G. Becket, and P. A. Crooks, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 8, Article 36 (2007).
20. S. Baboota and S. P. Agarwal, Preparation and characterization of meloxicam hydroxy propyl β-cyclodextrin inclusion complex. J. Incl. Phenomenon Macrocyclic Chem. 51, 21 (2005).
21. M. S. Nagarsenker, R. N. Meshram, and G. Ramprakash, Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: Enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J. Pharm. Pharmacol. 52, 949 (2000).
22. M. Amir and S. Kumar, Synthesis and evaluation of antiinflammatory, analgesic, ulcerogenic and lipid peroxidation properties of ibuprofen derivatives. Acta Pharm. 57, 31 (2007).
23. P. Jain and S. H. Yalkowsky, Solubilization of poorly soluble compounds using 2-pyrrolidone. Int. J. Pharm. 342, 1 (2007).
24. P. P. Shah, R. C. Mashru, Y. M. Rane, and A. C. Badhan, Design and optimization of artemether microparticles for bitter taste masking. Acta Pharm. 58, 379 (2008).
25. D. A. Chiappetta, A. M. Carcaboso, C. Bregni, M. Rubio, G. Bramuglia, and A. Sosnik, Indinavir-loaded pH-sensitive microparticles for taste masking: Toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 10, 1 (2009).
26. V. B. Patravale, A. A. Date, and R. M. Kulkarni, Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 56, 827 (2004).
27. S. K. Sahoo, J. Panyam, S. Prabha, and V. Labhasetwar, Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82, 105 (2002).
28. S. Galindo-Rodriguez, E. Allémann, H. Fessi, and E. Doelker, Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm. Res. 21, 1428 (2004).
29. C. Witschi and E. Doelker, Influence of the microencapsulation method and peptide loading on poly (lactic acid) and poly (lactic-co-glycolic acid) degradation during in vitro testing. J. Control. Release 51, 327 (1998).
30. B. C. Youan, A. Hussain, and N. T. Nguyen, Evaluation of sucrose esters as alternative surfactants in microencapsulation of proteins by the solvent evaporation method. AAPS PharmSciTech 5, 22 (2003).
31. M. Uner, S. A. Wissing, G. Yener, and R. H. Müller, Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie. 59, 331 (2004).
32. M. M. Ghorab, H. M. Abdel-Salam, M. A. El-Sayad, and M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 5, e59 (2004).
33. G. G. Liversidge, and P. Conzentino, Drug particle size reduction for decreasing gastric irritancy and enhancing gastric absorption of naproxen in rats. Int. J. Pharm. 125, 309 (1995).